BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML

News
Article

BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.

A new study of patients with chronic myeloid leukemia (CML) provides BCR-ABL1 transcript levels at time points within the first year of therapy that can best predict the achievement of a deep molecular response that lasts at least 2 years.

“The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation,” wrote study authors led by Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston. The investigators aimed to establish BCR-ABL1 levels within the first year of tyrosine kinase inhibitor therapy that could predict a sustained molecular response involving a BCR-ABL1 ˂ 0.0032% (MR4.5) for at least 2 years.

The analysis involved 603 CML patients enrolled in several clinical trials; depending on the trial, they were treated with imatinib, nilotinib, dasatinib, or ponatinib. The median follow-up was 103 months across the full cohort. The results were published in Cancer.

A total of 282 patients (47%) achieved a sustained MR4.5 at any time. For the achievement of MR4.5 at any time, the best-fit values for BCR-ABL1 levels were 0.051%, 0.019%, 0.007%, and 0.003% at 3, 6, 9, and 12 months, respectively. For achievement of a complete cytogenetic response within 1 year, the best-fit values were 0.087%, 0.037%, 0.016%, and 0.007%, respectively. For a major molecular response within 1 year, they were 0.059%, 0.024%, 0.010%, and 0.004%, respectively.

The minimum acceptable values for eventually achieving a sustained MR4.5 (meaning, the levels achieved by 95% of all those who reached the target endpoint) were 1.561%, 0.592%, 0.225%, and 0.085%, at 3, 6, 9, and 12 months, respectively.

At 5 years, the overall survival rate among those patients who achieved a sustained MR4.5 was 98%, compared with 89% among those who did not. At 10 years, these rates were 92% and 78%, respectively. Event-free survival, failure-free survival, and transformation-free survival were also better in patients who achieved a sustained MR4.5.

“The proper interpretation of transcript levels achieved early during the course of therapy may help to predict later responses and outcomes,” the authors wrote. “Models such as the one proposed here can be built to guide therapy for patients on a continuous basis.”

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content